Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk of developing Alzheimer disease.

Any time we have an opportunity to talk with Jeff Wolf, we take it – especially when the conversation tackles the highs and lows of leading a biotech startup. Currently the founder, chairman, and CEO at the clinical-stage immuno-oncology biopharma Heat Biologics (HTBX), Wolf previously founded or co-founded Avigen, Elusys, TyRx, Generation One, and Seed One Capital Ventures.

Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.

As marketability goes—and despite a growing unmet medical need—Lyme disease vaccine programs have suffered a futile fate. With its VLA15 candidate, French specialty vaccine company Valneva is trying to change that. 

Aiming to shed the legacy of an epic Alzheimer’s fail a few years ago, Axovant $AXGT is changing its name in a full corporate rebrand. The company announced Tuesday it will now be called Sio Gene Therapies as it completes what’s been a three-year pivot away from Alzheimer’s disease and toward, well, gene therapy.

Heat Biologics in Research Triangle Park is also working on a vaccine to combine with one like Pfizer’s to generate a more robust immune response.